Six-Month Pilot Study Demonstrates Improved Guideline Adherence Following Implementation of Standardized Cirrhosis Clinical Pathway
Key Highlights
- ➤4,251-patient pilot improved cirrhosis-care adherence across five community gastroenterology practices
- ➤Hepatic encephalopathy treatment adherence rose 7.8% relatively, from 60.2% to 64.9%
- ➤Chronic care management enrollment increased 9.4% relatively, from 11.7% to 12.8%
- ➤Office visit adherence improved 9.0% relatively, from 46.9% to 51.1%
- ➤Findings remain preliminary pending conference presentation and further peer-reviewed evaluation
Expert Statements
Peng-Sheng (Brian) Ting, MD and principal investigator of the pilot initiative
“These results highlight the value of a clinical pathway in helping providers deliver more consistent, guideline-based care for patients with cirrhosis”
Peng-Sheng (Brian) Ting, MD and principal investigator of the pilot initiative
“As the burden of liver disease continues to grow, broader adoption of proven care pathways may help close gaps in care, improve treatment adherence, and support better patient outcomes.”
Six-Month Pilot Study Demonstrates Improved Guideline Adherence Following Implementation of Standardized Cirrhosis Clinical Pathway PR Newswire
LAVAL, QC, Oct. 12, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), announced results from a multicenter pilot study evaluating a standardized clinical pathway for cirrhosis management demonstrated improved adherence to evidence-based monitoring and treatment practices across community gastroenterology settings. The findings will be presented as a poster at the American College of Gastroenterology (ACG) Annual Scientific Meeting & Postgraduate Course, taking place October 9-14, 2026, in Nashville, Tennessee.
Get started
Create a free account to read the full story.